A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Nevanimibe (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Millendo Therapeutics
- 12 Aug 2019 Status changed from recruiting to discontinued, as reported in a Millendo Therapeutics media release.
- 12 Aug 2019 According to a Millendo Therapeutics media release, the company plans to discontinue the study due to slower than anticipated enrollment and a reprioritization of resources.
- 23 Oct 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.